The application of Bayesian statistics in clinical trials_Chinese Journal of Evidence-Based Medicine

Authors：

JIAYIDAER Hu’an ^1,2 , YAO Minghong ² , LIU Yanmei ² , LIU Jiali ² ,  LI Ling ² ,  SUN Xin ^1,2

1. Department of Epidemiology and Biostatistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, P. R. China;
2. Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;

Corresponding author：

LI Ling, Email: liling@wchscu.cn; SUN Xin, Email: sunxin@wchscu.cn

Keywords：

Bayesian methods; Bayesian statistics; Clinical development; Clinical trials

DOI：

10.7507/1672-2531.202503199

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Statistical analysis of clinical trials has traditionally relied on frequentist methods, but Bayesian statistics has attracted considerable attention from regulators and researchers in recent years due to its unique advantages, and its use in clinical trials is increasing. Despite the obvious advantages of Bayesian statistics, the complexity of its design, implementation and analysis poses a number of challenges to its practical application, which may lead to an increased risk of unregulated use. This study aims to comprehensively sort out the application scenarios, common methods, special considerations and key elements of reporting of Bayesian statistical methods in clinical trials, with the aim of providing researchers with references for conducting Bayesian clinical trials, and promoting the scientific and rational application of Bayesian statistical methods in clinical trials.

Citation： JIAYIDAER Hu’an, YAO Minghong, LIU Yanmei, LIU Jiali, LI Ling, SUN Xin. The application of Bayesian statistics in clinical trials. Chinese Journal of Evidence-Based Medicine, 2025, 25(8): 952-959. doi: 10.7507/1672-2531.202503199 Copy

1.	Food and Drug Administration. The drug development process. 2020.
2.
3.	Yin G. Frequentist versus Bayesian statistics. Clinical trial design. New York: John Wiley & Sons, Ltd, 2011: 29-76.
4.
5.	FDA. Using Bayesian statistical approaches to advance our ability to evaluate drug products. 2023.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.	沈庆. 药物最大耐受剂量(MTD)探索方法的比较分析. 北京: 北京中医药大学, 2022.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.	Ahn C, Kang SH, Xie Y. Optimal biological dose for molecularly-targeted therapies. Wiley encyclopedia of clinical trials. New York: John Wiley & Sons, Ltd, 2007: 1-8.
35.
36.
37.
38.	Yuan Y, Nguyen HQ, Thall PF. Bayesian designs for phase Ⅰ-Ⅱ clinical trials. New York: Chapman and Hall/CRC, 2016.
39.	Pan H, Yuan Y. Optimal biological dose and phase Ⅰ/Ⅱ trials. Bayesian adaptive design for immunotherapy and targeted therapy. Singapore: Springer Nature, 2023: 47-52.
40.
41.
42.
43.	Lin R, Zhou Y, Yan F, et al. BOIN12: Bayesian optimal interval phase Ⅰ/Ⅱ trial design for utility-based dose finding in immunotherapy and targeted therapies. JCO Precis Oncol, 2020, 4: PO. 20.00257.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.	FDA. Guidance for the use of Bayesian statistics in medical device clinical trials. 2020.
61.
62.	Gatsonis C, Goodman S. Bayesian standards in science-standards for reporting of Bayesian analyses in the scientific literature. The BaSiS Group, 2001.
63.
64.

1. Food and Drug Administration. The drug development process. 2020.
2.
3. Yin G. Frequentist versus Bayesian statistics. Clinical trial design. New York: John Wiley & Sons, Ltd, 2011: 29-76.
4.
5. FDA. Using Bayesian statistical approaches to advance our ability to evaluate drug products. 2023.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22. 沈庆. 药物最大耐受剂量(MTD)探索方法的比较分析. 北京: 北京中医药大学, 2022.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34. Ahn C, Kang SH, Xie Y. Optimal biological dose for molecularly-targeted therapies. Wiley encyclopedia of clinical trials. New York: John Wiley & Sons, Ltd, 2007: 1-8.
35.
36.
37.
38. Yuan Y, Nguyen HQ, Thall PF. Bayesian designs for phase Ⅰ-Ⅱ clinical trials. New York: Chapman and Hall/CRC, 2016.
39. Pan H, Yuan Y. Optimal biological dose and phase Ⅰ/Ⅱ trials. Bayesian adaptive design for immunotherapy and targeted therapy. Singapore: Springer Nature, 2023: 47-52.
40.
41.
42.
43. Lin R, Zhou Y, Yan F, et al. BOIN12: Bayesian optimal interval phase Ⅰ/Ⅱ trial design for utility-based dose finding in immunotherapy and targeted therapies. JCO Precis Oncol, 2020, 4: PO. 20.00257.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60. FDA. Guidance for the use of Bayesian statistics in medical device clinical trials. 2020.
61.
62. Gatsonis C, Goodman S. Bayesian standards in science-standards for reporting of Bayesian analyses in the scientific literature. The BaSiS Group, 2001.
63.
64.

Previous Article
Interpretation of METhodological RadiomICs Score (METRICS)
Next Article
Application and practice of active comparator - new user design in real-world study

Chinese Journal of Evidence-Based Medicine

The application of Bayesian statistics in clinical trials

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content